Table 3.

Patient characteristics by antibody status and assay in patients who were RT-PCR positive

Patient No.AbbottFortressLFIATiming of Test Postdiagnosis (d)Age, yrSexEthnicityFirst Year Post-TransplantInduction Agent UsedImmunotherapy at Diagnosis
22NegativeNegativeNegative3553ManBAMEYesAlemtuzumabFK
29NegativeNegativeNegative2828WomanBAMEYesAlemtuzumabFK
36NegativeNegativeNegative2772ManWhiteYesAlemtuzumabFK, MMF
1NegativePositivePositive6563ManBAMENoUnknownFK, MMF
6NegativePositivePositive7048ManBAMENoAlemtuzumabFK
11NegativePositivePositive5546WomanBAMEYesAlemtuzumabFK, MMF
13NegativePositivePositive6079WomanBAMENoAlemtuzumabFK
16NegativePositivePositive4643ManBAMEYesAlemtuzumabFK, MMF
18NegativePositivePositive3767WomanBAMENoAlemtuzumabFK, MMF
31NegativePositivePositive2976ManWhiteNoAlemtuzumabFK, MMF
38NegativePositivePositive955ManBAMENoAlemtuzumabFK
33NegativePositiveNegative2166ManBAMEYesBasiliximabFK, MMF
7PositivePositiveNegative7350ManWhiteNoAlemtuzumabFK
26PositivePositiveNegative2849WomanBAMEYesAlemtuzumabFK, Pred
24 patients were positive across all three assays32 (22–41) (median)52±13 (mean)14 (58.3%) man5 (20.8%) White3 (12.5%) yes19 (79.2%) alemtuzumab9 (37.5%) (FK, MMF, Pred)
  • Paired historic sera from all patients were negative across the three assays. BAME, Black, Asian, and minority ethnic; FK, tacrolimus; MMF, mycophenolate mofetil; Pred, prednisolone.